The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Microbial drug discovery: 80 years of progress
Open accessAbstract
Microbes have made a phenomenal contribution to the health and well-being of people throughout the world. In addition to producing many primary metabolites, such as amino acids, vitamins and nucleotides, they are capable of making secondary metabolites, which constitute half of the pharmaceuticals on the market today and provide agriculture with many essential products. This review centers on these beneficial secondary metabolites, the discovery of which goes back 80 years to the time when penicillin was discovered by Alexander Fleming.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Bioactive Microbial Metabolites: A Personal View
Bérdy, J. (2005) · The Journal of Antibiotics · doi:10.1038/ja.2005.1 · Cited by 3,170
Fleming, A. (1929) · PubMed Central · Cited by 1,647
Alberts, A. W., Chen, J., Kuron, G., Hunt, V, Huff, J., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,628
Natural Products in Drug Discovery and Development
Cragg, G. M., Newman, D. J., & Snader, K. M. (1997) · Journal of Natural Products · doi:10.1021/np9604893 · Cited by 1,585
Farnsworth, N., Akerele, O., & Bingel, A. (1987) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(87)90016-x · Cited by 1,362
KINO, T., HATANAKA, H., HASHIMOTO, M., NISHIYAMA, M., GOTO, T., OKUHARA, M., KOHSAKA, M., AOKI, H., & IMANAKA, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1249 · Cited by 1,241
Isolating "Uncultivable" Microorganisms in Pure Culture in a Simulated Natural Environment
Kaeberlein, T., Lewis, K., & Epstein, S. S. (2002) · Science · doi:10.1126/science.1070633 · Cited by 1,237
Eisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198
Casewell, M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg313 · Cited by 948
Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J. (2008) · Nature Medicine · doi:10.1038/nm1788 · Cited by 882
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Ryan, K. J., & Ray, C. G. (2003) · Medical Entomology and Zoology · Cited by 760
Biotechnological advantages of laboratory-scale solid-state fermentation with fungi
H�lker, U., H�fer, M., & Lenz, J. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-003-1504-3 · Cited by 757
New antibiotics, bleomycin A and B.
Umezawa, H., Maeda, K., Takeuchi, T., & Okami, Y. (1966) · PubMed · Cited by 725
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
The future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O. D., Koupal, L. R., Liesch, J. M., Goetz, M., Lazarides, E., & Woods, C. M. (1995) · PubMed · Cited by 685
GERTH, K., BEDORF, N., HÖFLE, G., IRSCHIK, H., & REICHENBACH, H. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.560 · Cited by 631
New antibiotics from bacterial natural products
Clardy, J., Fischbach, M. A., & Walsh, C. T. (2006) · Nature Biotechnology · doi:10.1038/nbt1266 · Cited by 615
ANTIBIOTICS AS GROWTH PROMOTANTS:MODE OF ACTION
Gaskins, H. R., Collier, C. T., & Anderson, D. B. (2002) · Animal Biotechnology · doi:10.1081/abio-120005768 · Cited by 605
Lederberg, J. (2000) · Science · doi:10.1126/science.288.5464.287 · Cited by 521
Kowalski, R. J., Giannakakou, P., & Hamel, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2534 · Cited by 511
Invasive fungal infections: a review of epidemiology and management options
Enoch, D. A., Ludlam, H. A., & Brown, N. M. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46548-0 · Cited by 501
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Chemistry and Biochemistry of Microbial α‐Glucosidase Inhibitors
Truscheit, E., Frommer, W., Junge, B., Müller, L., Schmidt, D. D., & Wingender, W. (1981) · Angewandte Chemie International Edition in English · doi:10.1002/anie.198107441 · Cited by 472
Targeting mTOR signaling for cancer therapy
Huang, S. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00071-7 · Cited by 436
Bayer, E., Gugel, K. H., Hägele, K., Hagenmaier, H., Jessipow, S., König, W. A., & Zähner, H. (1972) · Helvetica Chimica Acta · doi:10.1002/hlca.19720550126 · Cited by 426
Curing metastatic testicular cancer
Einhorn, L. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072067999 · Cited by 387
Progress Towards the Discovery of Xanthine Oxidase Inhibitors
Borges, F., Fernandes, E., & Roleira, F. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023371229 · Cited by 372
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Dent, J. A., Davis, M. W., & Avery, L. (1997) · The EMBO Journal · doi:10.1093/emboj/16.19.5867 · Cited by 352
Epothilones: Mechanism of Action and Biologic Activity
Goodin, S., Kane, M. P., & Rubin, E. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.001 · Cited by 346
WEIBEL, E. K., HADVARY, P., HOCHULI, E., KUPFER, E., & LENGSFELD, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1081 · Cited by 341
Development of daptomycin for Gram-positive infections
Tally, F. P., & DeBruin, M. F. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.4.523 · Cited by 321
Livermore, D. M. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1465-0691.2004.1004.x · Cited by 314
Kremer, L., Douglas, J. D., Baulard, A. R., Morehouse, C., Guy, M. R., Alland, D., Dover, L. G., Lakey, J. H., Jacobs, W. R., Brennan, P. J., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000569200 · Cited by 256
Wang, Z., & Gleichmann, H. (1998) · Diabetes · doi:10.2337/diab.47.1.50 · Cited by 243
Antibiotics: Where did we go wrong?
Overbye, K. M., & Barrett, J. F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03285-4 · Cited by 223
Inhibitors of HIV-1 replication that inhibit HIV integrase.
Robinson, W. E., Reinecke, M. G., Abdel-Malek, S., Jia, Q., & Chow, S. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6326 · Cited by 222
Weed Control for the Preservation of Biological Diversity
Randall, J. M. (1996) · Weed Technology · doi:10.1017/s0890037x00040124 · Cited by 222
Design of angiotensin converting enzyme inhibitors
Cushman, D. W., & Ondetti, M. A. (1999) · Nature Medicine · doi:10.1038/13423 · Cited by 213
Therapeutic targets: MTOR and related pathways
Dancey, J. E. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.9.3175 · Cited by 194
Antifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153
Anticancer drug discovery and development throughout the world.
Schwartsmann, G., Ratain, M. J., Cragg, G. M. L., Wong, J. E., Saijo, N., Parkinson, D. R., Fujiwara, Y., Pazdur, R., Newman, D. J., Dagher, R. N., et al. (2002) · PubMed · Cited by 152
Doramectin — a potent novel endectocide
Goudie, A. C., Evans, N. A., Gration, K. A. F., Bishop, B. F., Gibson, S., HOLDOM, K. S., Kaye, B., Wicks, S. R., Lewis, D., Weatherley, A. J., et al. (1993) · Veterinary Parasitology · doi:10.1016/0304-4017(93)90218-c · Cited by 152
Annual Reports in Medicinal Chemistry
Cain, C. K., Doherty, A. M., Wood, A., Macor, J. E., & Desai, M. C. (2002) · Cited by 151
Raja, A., LaBonte, J. A., Lebbos, J., & Kirkpatrick, P. N. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1258 · Cited by 151
Update on antifungals targeted to the cell wall: focus on β-1,3-glucan synthase inhibitors
Georgopapadakou, N. H. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.2.269 · Cited by 149
Cragg, G. M. L., & Newman, D. J. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb11356.x · Cited by 137
Waksman, S. A., & Woodruff, H. B. (1941) · Journal of Bacteriology · doi:10.1128/jb.42.2.231-249.1941 · Cited by 134
History of the discovery of cyclosporin and of its early pharmacological development.
Borel, J. F. (2002) · PubMed · Cited by 123
McCallum, R. W., Cynshi, O., & INVESTIGATIVE TEAM (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03461.x · Cited by 118
Yang, S. S., Cragg, G. M. L., Newman, D. J., & Bader, J. P. (2001) · Journal of Natural Products · doi:10.1021/np0003995 · Cited by 110
Mishima, H., Ide, J., Muramatsu, S., & Ono, M. (1983) · The Journal of Antibiotics · doi:10.7164/antibiotics.36.980 · Cited by 107
Signal-transduction cascades as targets for therapeutic intervention by natural products
Cardenas, M. E., Sanfridson, A., Cutler, N. S., & Heitman, J. (1998) · Trends in Biotechnology · doi:10.1016/s0167-7799(98)01239-6 · Cited by 101
Ecker, D. J., Sampath, R., Willett, P., Wyatt, J. R., Samant, V., Massire, C., Hall, T. A., Hari, K. L., McNeil, J. A., Büchen-Osmond, C., et al. (2005) · BMC Microbiology · doi:10.1186/1471-2180-5-19 · Cited by 94
Trends in antibiotic research.
BOJARSKA‐DAHLIG, H. (1971) · PubMed · Cited by 84
Gastrointestinal and metabolic effects of amylase inhibition in diabetics
Boivin, M., Flourié, B., Rizza, R. A., Go, V. L. W., & DiMagno, E. P. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90426-x · Cited by 83
Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections
Eisenstein, B. I. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1159 · Cited by 79
Introduction: Problems with Antimicrobial Resistance in Gram‐Positive Cocci
Moellering, R. C. (1998) · Clinical Infectious Diseases · doi:10.1086/520288 · Cited by 76
Matabudul, D. K., Lumley, I. D., & Points, J. (2002) · The Analyst · doi:10.1039/b200872f · Cited by 75
Biosynthesis and Molecular Genetics of Clavulanic Acid
Jensen, S. E., & Paradkar, A. S. (1999) · Antonie van Leeuwenhoek · doi:10.1023/a:1001755724055 · Cited by 72
Daptomycin – a novel antibiotic against Gram-positive pathogens
LaPlante, K. L., & Rybak, M. J. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.11.2321 · Cited by 72
Recent Developments in Tetracycline Antibiotics
Sum, P., Sum, F. W., & Projan, S. J. (1970) · Current Pharmaceutical Design · doi:10.2174/138161280401221007113202 · Cited by 71
Caspofungin acetate: An antifungal agent
Hoang, A. D. (2001) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/58.13.1206 · Cited by 68
Butenyl-spinosyns, a natural example of genetic engineering of antibiotic biosynthetic genes
Hahn, D. R., Gustafson, G. D., Waldron, C., Bullard, B., Jackson, J. D., & Mitchell, J. C. (2005) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-005-0016-9 · Cited by 67
Natural and synthetic substances related to human health (IUPAC Technical Report)
Topliss, J. G., Clark, A., Ernst, E. K., Hufford, C. D., Johnston, G. A. R., Rimoldi, J. M., & Weimann, B. J. (2002) · Pure and Applied Chemistry · doi:10.1351/pac200274101957 · Cited by 65
Fulfilling the promise of biotechnology
Colwell, R. R. (2002) · Biotechnology Advances · doi:10.1016/s0734-9750(02)00011-3 · Cited by 64
Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs
Aggarwal, D., Fernández, M. L., & Soliman, G. A. (2006) · Metabolism · doi:10.1016/j.metabol.2006.01.017 · Cited by 58
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis
Nagano, J., Iyonaga, K., Kawamura, K., Yamashita, A., Ichiyasu, H., Okamoto, T., Suga, M., Sasaki, Y., & Kohrogi, H. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00070705 · Cited by 55
Cycling antibiotics may not be good for your health
Levin, B. R., & Bonten, M. J. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404970101 · Cited by 52
The Public Health Threat of Emerging Viral Disease
Morse, S. S. (1997) · Journal of Nutrition · doi:10.1093/jn/127.5.951s · Cited by 51
Enzyme Inhibitors of Marine Microbial Origin with Pharmaceutical Importance
Imada, C. (2004) · Marine Biotechnology · doi:10.1007/s10126-003-0027-3 · Cited by 48
Singh, N. (2005) · Medical Mycology · doi:10.1080/13693780500051984 · Cited by 45
Posaconazole: a new broad-spectrum antifungal agent
Kwon, D. S., & Mylonakis, E. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1167 · Cited by 44
Efficacy of Ivermectin against Strongyloides Stercoralis in Humans.
Shikiya, K., Kinjo, N., Uehara, T., Uechi, H., Ohshiro, J., ARAKAKI, T., Kinjo, F., Saitô, A., Mamoru, I. J. U., & Kobari, K. (1992) · Internal Medicine · doi:10.2169/internalmedicine.31.310 · Cited by 41
Evaluation and Development of Spinosyns to Control Ectoparasites on Cattle and Sheep
Kirst, H. A., Creemer, L. C., Naylor, S. A., Pugh, P., Snyder, D. E., Winkle, J. R., Lowe, L., Rothwell, J. T., Sparks, T. C., & Worden, T. V. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023393615 · Cited by 38
Role of Micafungin in the Antifungal Armamentarium
Ikeda, F., Tanaka, S., Ohki, H., et al. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780597970 · Cited by 34
Patchett, A. A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020424z · Cited by 33
A new hydroxylase system in Actinomadura sp cells converting compactin to pravastatin
Peng, Y., & Demain, A. L. (1998) · Journal of Industrial Microbiology & Biotechnology · doi:10.1038/sj.jim.2900539 · Cited by 19
Self-citationSTAPLEY, E. O., & Woodruff, H. B. (1982) · Cited by 19
Pentostatin in T-non-Hodgkin's lymphomas: Efficacy and effect on CD26+ T lymphocytes
Dang, N. H., Hagemeister, F. B., Duvic, M. A., Romaguera, J. E., Younes, A., Jones, D., Samuels, B. I., Fayad, L., Pro, B., Samaniego, F., et al. (2003) · Oncology Reports · doi:10.3892/or.10.5.1513 · Cited by 16
Targeted mTOR in Human Gynecologic Cancers
Chen, Y. (2007) · doi:10.29685/jcm.200708.0001 · Cited by 8
Case studies in current drug development: ‘glycylcyclines’
Sum, P. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.009 · Cited by 7
Cited by
Origins and evolution of antibiotic resistance
Davies, J., & Davies, D. (2010) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00016-10 · Cited by 5,784
Ben, Y., Fu, C., Hu, M., Liu, L., Wong, M. H., & Zheng, C. (2019) · Environmental Research · doi:10.1016/j.envres.2018.11.040 · Cited by 1,268
Ecological effects of antibiotics on natural ecosystems: A review
Grenni, P., Ancona, V., & Barra Caracciolo, A. (2018) · Microchemical Journal · doi:10.1016/j.microc.2017.02.006 · Cited by 1,257
Thoughts and facts about antibiotics: Where we are now and where we are heading
Bérdy, J. (2012) · The Journal of Antibiotics · doi:10.1038/ja.2012.27 · Cited by 1,165
Stewart, E. J. (2012) · Journal of Bacteriology · doi:10.1128/jb.00345-12 · Cited by 1,161
Metadata
- Authors
- Demain, A. L., & Sanchez, S.
- Venue
- The Journal of Antibiotics
- Published
- 2009-01
- Volume
- 62
- Issue
- 1
- Pages
- 5-16
- ISSN
- 0021-8820 (ISSN-L)
- 1881-1469
- OpenAlex
- W2023192368
- Cited by
- 1,002
- References
- 87
- FWCI
- 26.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.